SEARCH OUR PAGES

Immuno-Oncology

Immuno-Oncology

Immuno-Oncology Pipeline

OSE Immunotherapeutics’ immuno-oncology pipeline is comprised of four programs, three of which are currently in clinical status.

The most advanced program is its Phase 3 trial with TEDOPI®, a patented combination of 10 neo-epitopes. Tedopi® is being evaluated in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure.

A Phase 2 is also planned (early 2019) in pancreatic cancer in collaboration with the GERCOR, a leading clinical research association that includes 300 cancer centers in France.

OSE Immunotherapeutics is also investigating OSE-172, a first-in-class myeloid checkpoint inhibitor targeting the SIRPα / CD47 receptor pathway. In 2018, OSE Immunotherapeutics and Boehringer Ingelheim initiated a partnership covering the product’s development and commercialization in this promising new area of immuno-oncology.

Additionally, OSE Immunotherapeutics, in collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, is investigating the potential for OSE- 703, a cytotoxic monoclonal antibody against the alpha chain of Interleukin-7 Receptor (IL7R), in a number of solid tumor types with non-small cell lung cancer (NSCLC) as the primary cancer model.

Several new pipeline candidates should emerge in the near future in the immuno-oncology area.

Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
IMMUNO-ONCOLOGY
Tedopi®
Neo-Epitopes
NSCLC
EU-US-lsr
Tedopi®
Neo-Epitopes
Advanced pancreatic
Early 2019 Combo with PD1
OSE-172
SIRP-α
Various cancers
Q1 2019
OSE-703
IL-7 R
Various cancers
2019

Program

  • Indication NSCLC
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 EU-US-lsr
  • Partners
  • Indication Advanced pancreatic
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Early 2019 Combo with PD1
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC
  • Phase 1 Q1 2019
  • Phase 2
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC 2019
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • OSE-172

    +
  • OSE-703

    +
  • Tedopi®

    +